A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 17, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions
Chronic Graft-Versus-Host Disease
Interventions
DRUG

Adrixetinib

Administered orally

Trial Locations (8)

Unknown

Hospital Clinic de Barcelona, Barcelona

Hospital General Universitario Gregorio Maranon, Madrid

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

Hospital Universitario Virgen de la Arrixaca, Murcia

Clinica Universidad de Navarra, Pamplona

Hospital Universitario Marques de Valdecilla, Santander

Hospital Universitario Virgen del Rocio, Seville

Instituto de Investigacion Sanitaria, Valencia

All Listed Sponsors
lead

Qurient Co., Ltd.

INDUSTRY